Three Former FDA Investigators Revealed How They Actually Find What Companies Try to Hide

I asked three former FDA Investigators to do something most would never agree to in a public forum.

Tell me the techniques you actually used. Not the official inspection procedure. The specific methods you developed over years in the field that consistently revealed what facilities believed was hidden.

They agreed — on the condition I did not use their names. One of the four contributors to this conversation may or may not still be active in the Agency. I will leave that there.

What they shared is not in any guidance document. It is not taught in GMP training. It is the working intelligence of investigators who spent a combined 40-plus years finding exactly what companies did not want them to find.

I spent 14 years as an FDA Investigator myself. Then 13 years as a Quality executive on the industry side. Then 6 years watching outside auditors flag issues that would not survive a 483 review. I have seen both sides of this more times than I can count.

What I can tell you is this: the gap between what most companies prepare for and what a trained Investigator actually does when they walk through your door is significant. And it is not a document control gap.

What Investigators Are Actually Doing

The five techniques these former Investigators described operate across every phase of an inspection — before a single document is requested, during records review, and in the behavioral patterns your staff displays under observation.

None of them are visible in your quality system metrics. None of them show up on a gap assessment checklist. They are methodological — built from years of field experience — and they work precisely because most facilities have no idea they are being applied.

One former Investigator put it plainly during our conversation. The quote stopped me even though I already knew it from my own years in the field.

The facilities that handle inspections well are not always the most compliant. They are the ones that understand how the process actually works.

Why This Intelligence Is Rare

Former FDA Investigators do not typically share this information publicly. There is professional caution involved. There is the reality that some contributors may still have Agency relationships. And there is the simple fact that this kind of insider perspective has real commercial value — which is exactly why it does not appear in free compliance publications.

What was shared in these conversations represents a level of inspection intelligence that most Quality and Regulatory Affairs professionals will never encounter in their careers — unless they have spent time inside the Agency themselves.

I have. My colleagues have. And for the first time, we put it in writing.

The Five Techniques Are in The Investigator’s Lens

The full article covers all five techniques in detail — including the body language and behavioral patterns Investigators log before asking for a single document, the cross-referencing methodology that catches companies off guard more than any other approach, and the signature trail analysis that turns a records review into a data integrity investigation.

This is paid subscriber intelligence. It is not shared with free subscribers for a reason.

Read the full article here:
https://devaughnedwards.substack.com/p/three-former-fda-investigators-revealed?r=7sflcx

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831